Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
XYRA pairs a fast‑acting anti‑arrhythmic with wearable monitoring to transform atrial fibrillation care.
Cardiology
Technology Platform
Mixed ion‑channel blocker with esterase metabolism delivering a short half‑life and low tissue accumulation, paired with wearable cardiac monitoring for real‑time AF detection.
Opportunities
Potential to capture a large share of the AF market by offering a safer, fast‑acting drug combined with scalable wearable monitoring, and to generate partnership interest from pharma and med‑tech firms.
Risk Factors
Clinical efficacy and safety uncertainties, regulatory challenges for a drug‑device combo, and competition from existing anti‑arrhythmic agents and digital health platforms.
Competitive Landscape
Competes with amiodarone, dronedarone, and other rhythm‑control drugs, as well as wearable AF detection solutions; differentiation lies in budiodarone’s short half‑life and integrated monitoring approach.